Sichenzia Ross Ference LLP Represents Lexaria Bioscience Corp. in Close of $11 Million Underwritten Public Offering and NASDAQ Uplisting
Press Release – New York, NY – January 14, 2021 – Sichenzia Ross Ference LLP announced today that it represented Lexaria Bioscience Corp. (NASDAQ: “LEXX”), in a closing of an underwritten public offering of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit. Lexaria uses proprietary drug delivery technology, DehydraTECH™, improving the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. The gross proceeds from the offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses.
The offering was made pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (SEC).
H.C. Wainwright & Co. acted as the sole book-running manager for the Offering.
The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Avital Perlman, and associate Jacob Tabman and law clerk Zachary Weiss.
- Sichenzia Ross Ference LLP Represents Borqs Technologies, Inc. in $27 Million Private Placement - September 23, 2021
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp in $15 Million Registered Direct Offering of Molecular Data Inc. - September 22, 2021
- Sichenzia Ross Ference LLP Represents EzFill in $28.75 Million Initial Public Offering and NASDAQ Listing - September 20, 2021